Is monitoring of plasma 5-fluorouracil levels in metastatic / advanced colorectal cancer clinically effective? A systematic review
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Is monitoring of plasma 5-fluorouracil levels in metastatic / advanced colorectal cancer clinically effective? A systematic review
Authors
Keywords
5-fluorourcil, Colorectal cancer, Pharmacokinetic monitoring, Dose algorithms
Journal
BMC CANCER
Volume 16, Issue 1, Pages -
Publisher
Springer Nature
Online
2016-07-25
DOI
10.1186/s12885-016-2581-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A pilot study of pharmacokinetically guided dose management of capecitabine in CRC patients.
- (2017) Katsuya Makihara et al. JOURNAL OF CLINICAL ONCOLOGY
- A Review and Comparison of Methods for Recreating Individual Patient Data from Published Kaplan-Meier Survival Curves for Economic Evaluations: A Simulation Study
- (2015) Xiaomin Wan et al. PLoS One
- Cost Effectiveness Analysis of Pharmacokinetically-Guided 5-Fluorouracil in FOLFOX Chemotherapy for Metastatic Colorectal Cancer
- (2014) Daniel A. Goldstein et al. Clinical Colorectal Cancer
- Clinical Impact of Intensified 5-Fluorouracil-Based Chemotherapy Using a Prospective Pharmacokinetically-Guided Dosing Approach: Comparative Study in Elderly and Non-Elderly Patients with Metastatic Colorectal Cancer
- (2014) J. Duffour et al. JOURNAL OF CHEMOTHERAPY
- A Community-Based Multicenter Trial of Pharmacokinetically Guided 5-Fluorouracil Dosing for Personalized Colorectal Cancer Therapy
- (2014) J. N. Patel et al. ONCOLOGIST
- A general framework for parametric survival analysis
- (2014) Michael J. Crowther et al. STATISTICS IN MEDICINE
- Comparative evaluation of the My5-FU™ immunoassay and LC-MS/MS in monitoring the 5-fluorouracil plasma levels in cancer patients
- (2013) Barbara Büchel et al. CLINICAL CHEMISTRY AND LABORATORY MEDICINE
- Personalized Dosing via Pharmacokinetic Monitoring of 5-Fluorouracil Might Reduce Toxicity in Early- or Late-Stage Colorectal Cancer Patients Treated With Infusional 5–Fluorouracil-Based Chemotherapy Regimens
- (2013) Christina Leah B. Kline et al. Clinical Colorectal Cancer
- The Impact of Age, Sex and Socioeconomic Deprivation on Outcomes in a Colorectal Cancer Screening Programme
- (2013) David Mansouri et al. PLoS One
- Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves
- (2012) Patricia Guyot et al. BMC Medical Research Methodology
- Individual Fluorouracil Dose Adjustment in FOLFOX Based on Pharmacokinetic Follow-Up Compared With Conventional Body-Area-Surface Dosing: A Phase II, Proof-of-Concept Study
- (2012) Olivier Capitain et al. Clinical Colorectal Cancer
- Modeling the 5-Fluorouracil Area Under the Curve Versus Dose Relationship to Develop a Pharmacokinetic Dosing Algorithm for Colorectal Cancer Patients Receiving FOLFOX6
- (2012) R. R. Kaldate et al. ONCOLOGIST
- Preliminary observations indicate variable patterns of plasma 5-fluorouracil (5-FU) levels during dose optimization of infusional 5-FU in colorectal cancer patients
- (2011) Christina Leah Kline et al. CANCER BIOLOGY & THERAPY
- Body Surface Area–based Dosing of 5-Fluoruracil Results in Extensive Interindividual Variability in 5-Fluorouracil Exposure in Colorectal Cancer Patients on FOLFOX Regimens
- (2011) Jennifer Saam et al. Clinical Colorectal Cancer
- Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial
- (2011) Richard A Adams et al. LANCET ONCOLOGY
- Phase I, pharmacokinetic, and bone marrow drug-level studies of trimonthly 48-h infusion of high-dose 5-fluorouracil and leucovorin in patients with metastatic colorectal cancers
- (2010) Yunn-Fang Ho et al. ANTI-CANCER DRUGS
- Colorectal Cancer: National and International Perspective on the Burden of Disease and Public Health Impact
- (2010) Ziad F. Gellad et al. GASTROENTEROLOGY
- Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer
- (2010) Michel Ducreux et al. INTERNATIONAL JOURNAL OF CANCER
- Pharmacogenetic Assessment of Toxicity and Outcome in Patients With Metastatic Colorectal Cancer Treated With LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05
- (2010) Valérie Boige et al. JOURNAL OF CLINICAL ONCOLOGY
- Pharmacokinetically Guided Dose Adjustment of 5-Fluorouracil: A Rational Approach to Improving Therapeutic Outcomes
- (2009) M. Wasif Saif et al. JNCI-Journal of the National Cancer Institute
- Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer
- (2008) D. Cunningham et al. ANNALS OF ONCOLOGY
- Individual Fluorouracil Dose Adjustment Based on Pharmacokinetic Follow-Up Compared With Conventional Dosage: Results of a Multicenter Randomized Trial of Patients With Metastatic Colorectal Cancer
- (2008) Erick Gamelin et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and Efficacy of Oxaliplatin and Fluoropyrimidine Regimens With or Without Bevacizumab As First-Line Treatment of Metastatic Colorectal Cancer: Results of the TREE Study
- (2008) Howard S. Hochster et al. JOURNAL OF CLINICAL ONCOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started